Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January

December 28, 2017 By Law Offices of Thomas J. Lamb, P.A.

Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet.  These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs side effects, drug safety news, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, merck, new sglt2 inhibitors diabetes drugs, pfizer, Qtern, Segluromet, sglt2 inhibitors diabetes drugs, Steglatro, Steglujan, Synjardy, type 2 diabetes drugs, Xigduo

SGLT2 Inhibitors May Have an Increased Risk of Acute Renal Failure

October 31, 2017 By Law Offices of Thomas J. Lamb, P.A.

SGLT2 Inhibitors: A New Side Effect In previous articles, I have discussed SGLT2 inhibitor diabetes drugs such as Invokana, Farxiga, and Jardiance and the adverse events associated with them.  Such side effects include diabetic ketoacidosis (DKA) and lower-limb amputations. A recent study identified a new possible side effect of these drugs … [Read more...]

Filed Under: Unsafe Drugs Tagged With: acute renal failure, ARF, diabetes drugs, diabetes drugs renal failure, diabetes drugs side effects, FAERS, Farxiga, FDA Adverse Event Report System Database, Glyxambi, Invokamet, invokamet xr, Invokana, Jardiance, Qtern, sglt2 inhibitors, Sodium-Glucose-Cotransporter-2 Inhibitors, Synjardy, Synjardy XR, type 2 diabetes drugs, xigduo xr

J&J Tries to Expand Invokana Label to Include Cardiovascular Benefits

October 9, 2017 By Law Offices of Thomas J. Lamb, P.A.

Johnson & Johnson's, the drug manufacturer of diabetes drugs Invokana, Invokamet, and Invokamet XR, recently submitted a supplemental new drug application (sNDA) to the FDA to request expansion of the labels for these drugs. If granted, the new label would include a cardiovascular indication concerning the reduction of risk of cardiovascular … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, diabetes drugs amputation, diabetes drugs side effects, drug label changes, FDA, foot amputations, Heart Attacks, Invokamet, invokamet xr, Invokana, johnson & johnson's, leg amputations, nonfatal myocardial infarctions, sNDA, supplemental new drug application, toe amputations, type 2 diabetes drugs

Type 2 Diabetes Drugs Linked to Severe Joint Pain

June 2, 2017 By Law Offices of Thomas J. Lamb, P.A.

Health Canada recently warned about the risk of severe, debilitating joint pain as a result of taking type 2 diabetes medications called dipeptidylpeptidase-4 (DPP-4) inhibitors. This DPP-4 inhibitors class of drugs includes the following: Onglyza Kombiglyze XR Nesina Kazano Oseni Glyxambi Janumet (XR) Januvia … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs joint pain, diabetes drugs side effects, dipeptidylpeptidase-4 inhibitors, dpp-4 drugs, drugs side effects, Glyxambi, Janumet (XR), Januvia, Jentadueto, joint pain causes, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, Qtern, Tradjenta, type 2 diabetes drugs

Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti

March 17, 2017 By Law Offices of Thomas J. Lamb, P.A.

Invokana (canagliflozin) was approved by the FDA in 2013.  Invokamet (canagliflozin and metformin) was approved by the FDA in 2014.  Both of these drugs were approved for use by patients with Type 2 diabetes. In December 2015 the FDA issued this Drug Safety Communication: “FDA revises labels of SGLT2 inhibitors for diabetes to include warnings … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Acute Kidney Injury, diabetes drugs, Diabetic Ketoacidosis (DKA), Invokamet, Invokana, Ketoacidosis, Kidney Damage, type 2 diabetes drugs

EMA Warns that Some Diabetes Drugs Cause Increased Risk of Amputation

February 10, 2017 By Law Offices of Thomas J. Lamb, P.A.

Earlier today, February 10, 2017, the European Medicines Agency (EMA) released the findings of their Pharmacovigilance Risk Assessment Committee (PRAC) concerning the link between particular diabetes drugs and an increased risk of toe amputation. These diabetes drugs are part of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, drug injury lawsuits, drug side effects, EMA, Farxiga, forxiga, Glyxambi, Invokamet, Invokana, Jardiance, leg amputations, PRAC, toe amputations, type 2 diabetes drugs, xigduo xr

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.